Overview
Nuo Therapeutics
Here's a concept -- using the body's own faculties to heal wounds. Nuo Therapeutics has developed and markets an autologous platelet therapy, which uses a patient's own blood plasma to promote healing. Its AutoloGel System includes a centrifuge and blood draw kit. The centrifuge is used to separate key blood components, including platelets and growth factors, which are then combined with reagents to make a topical gel. When applied to
...
Read More a wound, the gel spurs the body's own healing process. AutoloGel has received FDA approval to treat chronic exuding wounds such as diabetic ulcers. Other products in Nuo's pipeline include an anti-inflammatory peptide that may help treat such diseases as rheumatoid arthritis.
Read Less
Read More a wound, the gel spurs the body's own healing process. AutoloGel has received FDA approval to treat chronic exuding wounds such as diabetic ulcers. Other products in Nuo's pipeline include an anti-inflammatory peptide that may help treat such diseases as rheumatoid arthritis.
Read Less
David E Jorden
See more contacts
Scientific Research and Development Services
,
Professional, Scientific, and Technical Services
,
Biotechnical research, commercial
,
Biological research
Accounting, Tax Preparation, Bookkeeping, and Payroll Services
,
Advertising, Public Relations, and Related Services
,
Architectural, Engineering, and Related Services
,
Computer Systems Design and Related Services
,
Legal Services
,
Management, Scientific, and Technical Consulting Services
,
Other Professional, Scientific, and Technical Services
,
Specialized Design Services
?
?
?
Modelled
?
Actual
$1.37 million
Actual
124.34%
$1
DEC
?
?
OTC:AURX
Contacts
Get in Touch with 2 Principals* and 4 Contacts
-
David E JordenSecretary and Chief Financial Officer and Chief Executive Officer
-
Contact 2?
-
Contact 3?
-
Contact 4?
Dynamic search and list-building capabilities
Real-time trigger alerts
Comprehensive company profiles
Valuable research and technology reports
Financial Statements
Dun & Bradstreet collects private company financials for more than 23 million companies worldwide. Find out more.
Financial data as of December 31, 2024 (12 month period) in USD
Annual Revenue 2024
$1.37 million
USD
Actual
All financial statement data is in millions except per share data | Source: Morningstar
| Cash Flow (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Operating Cash | -$2 | -$3 | -$4 |
| Net Investing Cash | -$0 | -$0 | -$0 |
| Net Financing Cash | $2 | $2 | $4 |
| Net Change in Cash | -$1 | -$1 | $1 |
| Cash at Beginning of Period | $1 | $2 | $1 |
| Cash at End of Period | $0 | $1 | $2 |
| Capital Expenditure | -$0 | -$0 | -$0 |
| Assets (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Assets | |||
| Cash and Cash Equivalents | $0 | $1 | $2 |
| Accounts Receivable | $0 | $0 | $0 |
| Inventories | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $0 |
| Asset Summary | |||
| Total Current Assets | $1 | $2 | $3 |
| Tangible Fixed Assets | $0 | $0 | $0 |
| Intangible Assets | $ | $ | $ |
| Total Assets | $1 | $2 | $3 |
| Liabilities (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current Liabilities | |||
| Accounts Payable | $0 | $0 | $0 |
| Short-Term Debt | $ | $ | $ |
| Other Current Liabilities | $0 | $0 | $0 |
| Liability Summary | |||
| Total Current Liabilities | $1 | $1 | $1 |
| Long-Term Debt | $ | $ | $ |
| Other Long-Term Liabilities | $ | $ | -$0 |
| Total Liabilities | $1 | $1 | $1 |
| Stakeholder's Equity (mil) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Equity | |||
| Common Stock | $0 | $0 | $0 |
| Retained Earnings | -$32 | -$30 | -$27 |
| Equity Summary | |||
| Total Equity | $1 | $1 | $2 |
| Shares Outstanding | 46,816,114 | 44,241,516 | 41,799,016 |